As reported here, earlier this month the U.S. Drug Enforcement Administration (DEA) issued a decision declining to transfer marijuana out of Schedule I. As marijuana remains a Schedule I...07 September 2016
Key developments in “reverse payment” dispute: the Supreme Court agrees to weigh in, and a NJ court refuses to condemn exclusive authorized generics
This past week saw two key developments in the legal dispute over patent settlements including so-called “reverse payments.” First, the Supreme Court agreed to review an Eleventh Circuit decision dismissing a case brought by the Federal Trade Commission (FTC) challenging a patent settlement. Second, a district court in New Jersey issued the first decision to consider the legal treatment of a commitment by a brand name manufacturer to a generic company not to license any other generic companies the right to sell an authorized generic. For our analysis of these developments, please click here.